Five things for pharma marketers to know: Tuesday, October 11, 2016

1. Bristol-Myers Squibb's immuno-oncology therapy Opdivo failed to show superiority to chemotherapy in a lung-cancer trial. In a study targeting a similar group of patients, Merck's Keytruda lowered the risk of death or cancer progression by 50%. Shares of Ono, BMS' partner, dropped after the release of the study. (Bloomberg)

2. A hedge fund, Partner Fund Management, sued Theranos and its founder, Elizabeth Holmes, for allegedly misleading the company to invest almost $100 million in the health tech startup. (WSJ)

3. Takeda Pharmaceutical Company and Crescendo Biologics said they will partner to develop and commercialize humabody-based therapeutics for cancer treatment. Crescendo has a number of cancer drugs in its pipeline.

4. The number of dementia patients hooked up to breathing machines in U.S. nursing homes increased by 50% from 2000 to 2013, but the mortality rate hasn't changed, according to a new study. Out of every 1,000 nursing home residents with dementia, 78 were using mechanical ventilators in 2013, compared to only 39 in 2000. (Reuters)

5. Roche said it received FDA priority review for Lucentis, its eye drug, as a treatment for myopic choroidal neovascularization, a condition of near-sightedness that can lead to blindness. (Reuters)